Lundbeck acquired Abide Therapeutics and their lead compound ABX-1431
Updated: Jun 3, 2019
Lundbeck has completed the acquisition of US-based biotech company Abide Therapeutics and the lead compound ABX-1431.
On May 6th, 2019 Lundbeck announced that it was acquiring Abide Therapeutics. Abide Therapeutics is currently working the serine hydrolases; the acquisition helps
Lundbeck to work on new classes of drugs for a range of therapeutic activities.
Also, Lundbeck gets the advanced compound ABX-1431 first-in-class MAG Lipase inhibitor used for the treatment of Tourette Syndrome and neuropathic pain.